No Data
No Data
The positive rate of influenza viruses nationwide continues to rise, and the sales of Against Influenza drugs continue to grow.
① According to the latest data from the China Center for Disease Control and Prevention, the positivity rate of influenza viruses continues to rise, with over 99% being type A influenza. ② As the number of influenza infections increases, the sales of antiviral drugs against influenza have also been growing recently. Currently, the antiviral flu medications available domestically mainly include Oseltamivir, Abidol, Mabalaosavir, Zanamivir, and Peramivir.
Individual Investors Among Guangdong Zhongsheng Pharmaceutical Co., Ltd.'s (SZSE:002317) Largest Stockholders and Were Hit After Last Week's 3.6% Price Drop
Guangdong Zhongsheng Pharmaceutical (002317.SZ): The phase II clinical trial of the Innovative Drug RAY1225 injection for lowering blood sugar has obtained top-line analysis data results from the sub-study.
On December 30, Glonghui reported that Guangdong Zhongsheng Pharmaceutical (002317.SZ) announced that its holding subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd. (referred to as "Zhongsheng Ruichuang"), has independently developed an innovative peptide drug, RAY1225 injection, which is used in the Phase II clinical trial for type 2 diabetes patients, and has recently obtained the top-line analysis data from the sub-study. Preliminary results indicate that RAY1225 injection has shown positive efficacy and good safety in adult participants with type 2 diabetes in China, with the trial results being ideal and achieving the expected objectives.
Guangdong Zhongsheng Pharmaceutical (002317.SZ): A subsidiary has obtained a patent certificate in Europe.
On December 12, Gelonghui reported that Guangdong Zhongsheng Pharmaceutical (002317.SZ) announced that its holding subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd. (referred to as "Zhongsheng Ruichuang"), received a patent certificate issued by the European Patent Office. The invention is titled: TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME (tyrosine kinase inhibitor and pharmaceutical composition containing the same). This patent is for Zhongsheng Ruichuang.
Guangdong Zhongsheng Pharmaceutical (002317.SZ): the existing product Fumaric Acid Chlorpheniramine Maleate Oral Solution is a pediatric dosage form.
Guangdong Zhongsheng Pharmaceutical (002317.SZ) stated on the investor interaction platform on November 14th that, according to the "Guidelines for the Diagnosis and Treatment of Atopic Dermatitis in China (2020)", oral antihistamines are recommended for the auxiliary treatment of atopic dermatitis itching. The company's existing product, Chlorpheniramine Malate Oral Solution, is a pediatric formulation. The company is also actively focusing on the research and development, production, and sales of pediatric medications.
Guangdong Zhongsheng Pharmaceutical (002317.SZ): Antibiotic varieties include cefradine dispersible tablets, cefaclor capsules, cephaloridine capsules, doxycycline hydrochloride tablets and other products
Gelonghui reported on November 14 that guangdong zhongsheng pharmaceutical (002317.SZ) stated on the investor interaction platform that the products used to treat mycoplasma pneumonia and symptoms caused by the disease such as fever, cough, headache, and sore throat include: azithromycin granules, guangdong zhongsheng pharmaceutical pill series products, ibuprofen tablets, acetaminophen tablets, and cough loquat syrup, among others. The company's antibiotic varieties include cefixime dispersible tablets, amoxicillin capsules, cephalexin capsules, and doxycycline hydrochloride tablets.
Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SZSE:002317) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected
